Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$13,458 Mln
P/E Ratio
--
P/B Ratio
5.68
Industry P/E
--
Debt to Equity
1.07
ROE
-0.3 %
ROCE
-18.93 %
Div. Yield
0 %
Book Value
14.92
EPS
-7.69
CFO
$7,410.11 Mln
EBITDA
$427.43 Mln
Net Profit
$-315.44 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Illumina (ILMN)
| -36.55 | -17.68 | -36.72 | -34.54 | -36.85 | -17.26 | -7.96 |
|
BSE Sensex
| -2.43 | 0.54 | -3.62 | 6.02 | 9.68 | 21.97 | 10.37 |
|
S&P Midcap 400
| -5.01 | -7.72 | -4.67 | 0.72 | 3.05 | 17.58 | 6.88 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Illumina (ILMN)
| -1.33 | -31.14 | -46.85 | 2.82 | 11.53 | 10.61 | 37.04 |
|
S&P Midcap 400
| 12.12 | 14.45 | -14.48 | 23.21 | 11.81 | 24.05 | -12.43 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 231.85 | 66,555.02 | 39.02 | 6.76 | |
| 70.95 | 41,352.88 | 30.06 | 50.15 | |
| 420.62 | 34,332.70 | 39.6 | 57.66 | |
| 235.83 | 38,504.55 | 54.77 | 12.96 |
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and... consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California. Address: 5200 Illumina Way, San Diego, CA, United States, 92122 Read more
CEO & Director
Mr. Jacob Thaysen Ph.D.
CEO & Director
Mr. Jacob Thaysen Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Illumina Inc (ILMN) stood at $ 6,303 Mln as on 31-Dec-24
The share price of Illumina Inc (ILMN) is $84.79 (NASDAQ) as of 20-Mar-2025 16:06 EDT. Illumina Inc (ILMN) has given a return of -36.85% in the last 3 years.
Illumina Inc (ILMN) has a market capitalisation of $ 13,458 Mln as on 20-Mar-2025. As per Value Research classification, it is a Mid Cap company.
Since, TTM earnings of Illumina Inc (ILMN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Illumina Inc (ILMN) and enter the required number of quantities and click on buy to purchase the shares of Illumina Inc (ILMN).
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California. Address: 5200 Illumina Way, San Diego, CA, United States, 92122
The CEO & director of Mr. Jacob Thaysen Ph.D.. is Illumina Inc (ILMN), and CFO & Sr. VP is Mr. Jacob Thaysen Ph.D..
There is no promoter pledging in Illumina Inc (ILMN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
6,440
|
|
|
4,283
|
|
|
3,592
|
|
|
3,571
|
| Illumina Inc. (ILMN) | Ratios |
|---|---|
|
Return on equity(%)
|
-30.13
|
|
Operating margin(%)
|
-24.68
|
|
Net Margin(%)
|
-27.97
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Illumina Inc (ILMN) was $-1,223 Mln.
$-0.17
(
